Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Naunyn Schmiedebergs Arch Pharmacol ; 384(1): 39-45, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21533991

ABSTRACT

Dopaminergic stabilizers may be conceptualized as drugs with normalizing effects on dopamine-mediated behaviours and neurochemical events. (S)-(-)-OSU6162 (OSU6162) and ACR16 are two structurally related compounds ascribed such properties, principally because of their stabilizing effects on motor activity in rodents. Reports in the literature indicate possible partial D2 receptor agonist effects using various in vitro systems. This study aimed to measure D2 receptor antagonist and agonist effects of OSU6162 and ACR16 in vivo. To address this, we have studied the effects of both compounds on prolactin secretion in drug-naive and dopamine-depleted rats; dopamine depletion was induced by pretreatment with reserpine plus α-methyl-DL: -p-tyrosine. We find that OSU6162 and ACR16 both stimulate prolactin secretion in drug-naive rats with OSU6162 being considerably more potent and efficacious. Both compounds show a non-significant trend towards reversal of the increased secretion caused by dopamine depletion, whereas the D2 receptor antagonist haloperidol further increased prolactin secretion. Thus, this study suggests that OSU6162 and ACR16 act as D2 receptor antagonists under normal conditions in vivo, possibly with minor agonist effects in a state of dopamine depletion.


Subject(s)
Dopamine D2 Receptor Antagonists , Dopamine/deficiency , Lactotrophs/drug effects , Piperidines/pharmacology , Prolactin/blood , Receptors, Dopamine D2/agonists , Animals , Aripiprazole , Dopamine Agonists/administration & dosage , Dopamine Agonists/pharmacology , Dopamine Antagonists/administration & dosage , Dopamine Antagonists/pharmacology , Haloperidol/administration & dosage , Haloperidol/pharmacology , Hyperprolactinemia/blood , Hyperprolactinemia/chemically induced , Lactotrophs/metabolism , Male , Methyltyrosines/administration & dosage , Methyltyrosines/pharmacology , Piperazines/administration & dosage , Piperazines/pharmacology , Piperidines/administration & dosage , Prolactin/metabolism , Quinolones/administration & dosage , Quinolones/pharmacology , Rats , Rats, Sprague-Dawley , Reserpine/administration & dosage , Reserpine/pharmacology
2.
J Neural Transm (Vienna) ; 115(6): 899-908, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18351286

ABSTRACT

Dopaminergic stabilizers can be defined as drugs that stimulate or inhibit dopaminergic signalling depending on the dopaminergic tone. (-)-OSU6162 and ACR16 appear to possess such a profile. They have been proposed to act as partial dopamine receptor agonists or as antagonists with preferential action on dopaminergic autoreceptors. Previous studies have shown either stimulation or inhibition of behaviour in response to (-)-OSU6162 and ACR16, which has been suggested to reflect their dual effects on dopaminergic signalling. The aims of the present work are to (1) examine the relation between behavioural response to these drugs and activity baseline, and (2) test the suggested mechanisms of action by means of close comparisons with the known partial D2-receptor agonists (-)-3-PPP and aripiprazole, and the D2 autoreceptor preferring antagonist amisulpride with respect to effects on behaviour. From the results of these experiments it can be concluded that: (1) The direction of the response to (-)-OSU6162 and ACR16 is dependent on activity baseline, which in turn, under physiological conditions, is determined primarily by test arena size of and degree of habituation to the environment. (2) The effects of (-)-OSU6162 and ACR16 cannot be explained on the basis of either partial dopamine receptor agonism or preferential dopamine autoreceptor antagonism. Nevertheless, the current data suggest at least two different D2-receptor-associated targets which mediate opposite effects on activity. This result fits in with a mechanism proposed from a recent in vitro study, according to which (-)-OSU6162 has a dual action on dopamine D2 receptors, (a) an allosteric effect causing an enhanced response to dopamine, and (b) the previously proposed orthosteric effect antagonizing the action of dopamine.


Subject(s)
Brain/drug effects , Brain/metabolism , Dopamine/metabolism , Motor Activity/drug effects , Piperidines/pharmacology , Receptors, Dopamine D2/drug effects , Animals , Dopamine Agents/pharmacology , Dopamine Agonists/pharmacology , Dopamine Antagonists/pharmacology , Dopamine D2 Receptor Antagonists , Dose-Response Relationship, Drug , Drug Interactions/physiology , Habituation, Psychophysiologic/drug effects , Habituation, Psychophysiologic/physiology , Male , Motor Activity/physiology , Rats , Rats, Sprague-Dawley , Receptors, Dopamine D2/agonists , Receptors, Dopamine D2/metabolism , Synaptic Transmission/drug effects , Synaptic Transmission/physiology
3.
Mol Reprod Dev ; 74(10): 1317-26, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17342739

ABSTRACT

Progesterone is a survival factor in rat periovulatory granulosa cells. The mechanisms involved are unclear but progesterone receptor (PGR) antagonists have been shown to inhibit cholesterol synthesis and induce apoptosis. Furthermore, reports suggest that statins induce apoptosis by inhibition of protein isoprenylation. Statins inhibit the rate-limiting step of the cholesterol synthesis, thereby reducing availability of intermediates used for the post-translational isoprenylation process. It has been suggested that PGR antagonists in a similar manner induce apoptosis by decreasing cholesterol synthesis and thereby protein isoprenylation. In this study we hypothesized that the mechanism by which the nuclear PGR antagonist Org 31,710 induces apoptosis in rat periovulatory granulosa cells, is by decreasing cholesterol synthesis and thereby general cell protein isoprenylation. Incubation of isolated granulosa cells with Org 31,710 or simvastatin for 22 hr resulted in increased apoptosis and reduced cholesterol synthesis. However, simvastatin caused a substantial inhibition of cholesterol synthesis after 6 hr in culture without inducing apoptosis. In contrast, Org 31,710 had only a modest effect on cholesterol synthesis after 6 hr while it significantly induced apoptosis. Addition of isoprenylation substrates partially reversed apoptosis induced by simvastatin and to a lesser extent apoptosis induced by Org 31,710. In addition, and in contrast to Org 31,710, simvastatin caused a decrease in isoprenylation of a selected isoprenylation marker protein, the Ras-related protein RAB11. In conclusion, we demonstrate that the PGR antagonist inhibits cholesterol synthesis in granulosa cells but reduced protein isoprenylation is not the mediating mechanism of increased apoptosis as previously hypothesized.


Subject(s)
Apoptosis/drug effects , Estrenes/pharmacology , Furans/pharmacology , Granulosa Cells/drug effects , Protein Prenylation/drug effects , Receptors, Progesterone/antagonists & inhibitors , Animals , Cells, Cultured , Cholesterol/metabolism , Female , Granulosa Cells/cytology , Granulosa Cells/metabolism , Hormone Antagonists/pharmacology , Hypolipidemic Agents/pharmacology , Protein Prenylation/physiology , Rats , Rats, Sprague-Dawley , Simvastatin/pharmacology
4.
Mol Reprod Dev ; 73(10): 1277-83, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16868926

ABSTRACT

Progesterone receptor (PR) stimulation promotes survival in human and rat periovulatory granulosa cells. PR antagonists, Org 31710 and RU 486, both increase apoptosis and decrease cholesterol synthesis in these cells. The decrease in cholesterol synthesis also causes decreased synthesis of other products branching from the cholesterol synthesis pathway, including substrates for protein prenylation. In this study we focus on the link between apoptosis and prenylation in human periovulatory granulosa cells. A decreased cholesterol synthesis and increased apoptosis was verified in experiments with human periovulatory granulosa cells treated with the PR antagonists Org 31710 or RU 486 by measuring caspase-3/7 activity and incorporation of 14C-acetate into cholesterol and progesterone. Correspondingly, specific inhibition of cholesterol synthesis in periovulatory human granulosa cells using HMG-CoA reductase inhibitors (lovastatin or simvastatin) increased apoptosis, measured as caspase-3/7 activity. The increase in apoptosis caused by simvastatin or Org 31710 was partially reversed by addition of the protein prenylation precursors farnesol or geranylgeraniol. In addition, the prenylation inhibitors FTI R115777 and GGTI 2147 increased apoptosis in these cells. In conclusion our data suggest that PR antagonists increase apoptosis and reduce cholesterol synthesis in periovulatory granulosa cells and that the resulting depletion of substrates for protein prenylation may contribute to the increased apoptosis sensitivity.


Subject(s)
Apoptosis , Cholesterol/biosynthesis , Granulosa Cells/physiology , Protein Prenylation/drug effects , Apoptosis/drug effects , Cells, Cultured , Diterpenes/pharmacology , Estrenes/pharmacology , Farnesol/pharmacology , Farnesyltranstransferase/antagonists & inhibitors , Female , Furans/pharmacology , Granulosa Cells/drug effects , Granulosa Cells/metabolism , Hormone Antagonists/pharmacology , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Imidazoles/pharmacology , Leucine/analogs & derivatives , Leucine/pharmacology , Mifepristone/pharmacology , Ovulation , Quinolones/pharmacology , Receptors, Progesterone/antagonists & inhibitors
5.
Am J Physiol Endocrinol Metab ; 291(1): E59-72, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16449295

ABSTRACT

Progesterone and its interaction with nuclear progesterone receptors (PR) PR-A and PR-B play a critical role in the regulation of female reproductive function in all mammals. However, our knowledge of the regulation and possible cellular function of PR protein isoforms in the fallopian tube and uterus in vivo is still very limited. In the present study, we revealed that equine chorionic gonadotropin (eCG) treatment resulted in a time-dependent increase in expression of both isoforms, reaching a maximal level at 48 h in the fallopian tube. Regulation of PR-A protein expression paralleled that of PR-B protein expression. However, in the uterus PR-B protein levels increased and peaked earlier than PR-A protein levels after eCG treatment. With prolonged exposure to eCG, PR-B protein levels decreased, whereas PR-A protein levels continued to increase. Furthermore, subsequent treatment with human (h)CG decreased the levels of PR protein isoforms in both tissues in parallel with increased endogenous serum progesterone levels. To further elucidate whether progesterone regulates PR protein isoforms, we demonstrated that a time-dependent treatment with progesterone (P(4)) decreased the expression of PR protein isoforms in both tissues, whereas decreases in p27, cyclin D(2), and proliferating cell nuclear antigen protein levels were observed only in the uterus. To define the potential PR-mediated effects on apoptosis, we demonstrated that the PR antagonist treatment increased the levels of PR protein isoforms, induced mitochondrial-associated apoptosis, and decreased in epidermal growth factor (EGF) and EGF receptor protein expression in both tissues. Interestingly, immunohistochemistry indicated that the induction of apoptosis by PR antagonists was predominant in the epithelium, whereas increase in PR protein expression was observed in stromal cells of both tissues. Taken together, these observations suggest that 1) the tissue-specific and hormonal regulation of PR isoform expression in mouse fallopian tube and uterus, where they are potentially involved in regulation of mitochondrial-mediated apoptosis depending on the cellular compartment; and 2) a possible interaction between functional PR protein and growth factor signaling may have a coordinated role for regulating apoptotic process in both tissues in vivo.


Subject(s)
Fallopian Tubes/physiology , Receptors, Progesterone/physiology , Uterus/physiology , Animals , Apoptosis/physiology , Blotting, Western , Chorionic Gonadotropin/physiology , Epidermal Growth Factor/antagonists & inhibitors , Epidermal Growth Factor/biosynthesis , Epidermal Growth Factor/genetics , ErbB Receptors/antagonists & inhibitors , ErbB Receptors/biosynthesis , ErbB Receptors/genetics , Estradiol/blood , Estrenes/pharmacology , Fallopian Tubes/drug effects , Fallopian Tubes/metabolism , Female , Furans/pharmacology , Gene Expression Regulation , Hormone Antagonists/pharmacology , Horses , Immunohistochemistry , Mice , Mice, Inbred C57BL , Mifepristone/pharmacology , Organ Size/drug effects , Organ Size/physiology , Progesterone/blood , Progesterone/pharmacology , Receptors, Progesterone/antagonists & inhibitors , Receptors, Progesterone/biosynthesis , Uterus/drug effects , Uterus/metabolism
6.
Mol Reprod Dev ; 73(1): 50-60, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16175636

ABSTRACT

The small ubiquitin-related modifier-1 (SUMO-1) with broad cellular expression has been implicated in a range of cellular processes, such as cell proliferation, differentiation, and apoptosis. As shown recently, SUMO-1 is expressed and regulated by gonadotropins, in particular an ovulatory hCG stimulus in mouse granulosa cells in vivo. To test the hypothesis that modulation of granulosa cell apoptosis changes SUMO-1 expression during granulosa cell differentiation in the mouse ovary, we demonstrate that progesterone receptor (PR) proteins are absent in pre-ovulatory granulosa cell nuclei, whereas they are expressed in periovulatory granulosa cell nuclei in parallel with decreases in SUMO-1 expression, caspase-3 activation, and DNA fragmentation in vivo. Second, treatment with either PR antagonists or a cell permeable ceramide analog consistently increases SUMO-1 expression in parallel with an increase in apoptosis as well as a decrease in cell proliferation in periovulatory granulosa cells in vitro. However, we do not observe an increase in SUMO-1 expression in pre-ovulatory granulosa cells that have undergone the same treatment. Third, we have also demonstrated, in pre-ovulatory granulosa cells in vitro, neither induction of spontaneous apoptosis nor the protective effect of EGF against spontaneous apoptosis changes SUMO-1 protein expression. Fourth, we show that induction of apoptosis enhances SUMO-1 conjugation in periovulatory granulosa cells in vitro, pointing to the pivotal link between the SUMO-1 conjugation and cell death. Taken together, our observations suggest that SUMO-1 via sumoylation has an important role in the regulation of granulosa cell apoptosis during granulosa cell differentiation in the mouse ovary.


Subject(s)
Apoptosis/physiology , Granulosa Cells/metabolism , SUMO-1 Protein/genetics , Animals , Caspase 3 , Caspases/metabolism , Cell Nucleus/metabolism , Cells, Cultured , Ceramides/physiology , Female , Mice , Mice, Inbred C57BL , Receptors, Progesterone/metabolism , SUMO-1 Protein/biosynthesis
7.
Biol Reprod ; 72(3): 538-45, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15385411

ABSTRACT

Progesterone-receptor (PR) stimulation promotes survival in rat and human periovulatory granulosa cells. To investigate the mechanisms involved, periovulatory rat granulosa cells were incubated in vitro with or without the PR-antagonist Org 31710. Org 31710 caused the expected increase in apoptosis, and expression profiling using cDNA microarray analysis revealed regulation of several groups of genes with functional and/or metabolic connections. This regulation included decreased expression of genes involved in follicular rupture, increased stress responses, decreased angiogenesis, and decreased cholesterol synthesis. A decreased cholesterol synthesis was verified in experiments with both rat and human periovulatory granulosa cells treated with the PR-antagonists Org 31710 or RU 486 by measuring incorporation of [14C]acetate into cholesterol, cholesterol ester, and progesterone. Correspondingly, specific inhibition of cholesterol synthesis in periovulatory rat granulosa cells using 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (lovastatin, mevastatin, or simvastatin) increased apoptosis, measured as DNA fragmentation and caspase-3/7 activity. The increase in apoptosis caused by simvastatin was reversed by addition of the cholesterol synthesis-intermediary mevalonic acid. These results show that PR antagonists reduce cholesterol synthesis in periovulatory granulosa cells and that cholesterol synthesis is important for granulosa cell survival.


Subject(s)
Apoptosis/physiology , Cholesterol/biosynthesis , Granulosa Cells/metabolism , Ovulation/physiology , Receptors, Progesterone/metabolism , Animals , Apoptosis/drug effects , Cell Survival/physiology , Estrenes/pharmacology , Female , Furans/pharmacology , Gene Expression Profiling , Gene Expression Regulation , Granulosa Cells/drug effects , Hormone Antagonists/pharmacology , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , In Vitro Techniques , Mifepristone/pharmacology , Oligonucleotide Array Sequence Analysis , Rats , Rats, Sprague-Dawley , Receptors, Progesterone/antagonists & inhibitors , Signal Transduction/physiology
8.
Endocrinology ; 145(1): 384-92, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14500579

ABSTRACT

The small ubiquitin-related modifier-1 (SUMO-1) is a member of a family of ubiquitin-related proteins that have effects on several important physiological functions, including reproduction. However, the regulation of SUMO-1 expression and functional distribution of SUMO-1 in vivo remain poorly understood. In the present study, we show that SUMO-1 protein is widely expressed in various tissues. In the ovary, the expression of SUMO-1 protein is suppressed around ovulation, in both the whole ovary and the granulosa cells, after gonadotropin treatment. Additionally, when the ovulatory signal, the endogenous LH surge, is blocked in vivo by pentobarbitone sodium, the expression of SUMO-1 protein in granulosa cells is increased. This effect is reversed when the missing endogenous LH surge is substituted by human chorionic gonadotropin treatment. Our findings provide the first evidence that inhibition of SUMO-1 expression is regulated by LH receptor stimulation in granulosa cells concomitant with ovulation in the mouse ovary. Furthermore, the levels of SUMO-1 protein are increased in granulosa cells treated with progesterone receptor (PR) antagonists both in vivo and in vitro, demonstrating that SUMO-1 expression is regulated by functional PR. SUMO-1 interacts with nuclear receptors in vitro, and LH receptor-mediated induction of PR is crucial for ovulation. SUMO-1 and PR are coexpressed and can be coprecipitated, providing additional evidence for a direct interaction between SUMO-1 and PR in periovulatory granulosa cells in vivo. These results suggest that a functional link between SUMO-1 and PR is of physiological importance for the local modulation of PR-mediated events in the ovary.


Subject(s)
Granulosa Cells/physiology , Ovulation/physiology , Receptors, LH/metabolism , Receptors, Progesterone/metabolism , SUMO-1 Protein/genetics , SUMO-1 Protein/metabolism , Animals , Estrenes/pharmacology , Female , Furans/pharmacology , GABA Modulators/pharmacology , Gene Expression/drug effects , Gene Expression/physiology , Male , Mice , Mice, Inbred C57BL , Pentobarbital/pharmacology , Receptors, Progesterone/antagonists & inhibitors , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...